A Surprising Discovery: Slimming Drugs for Heart Health

It’s the largest study of its kind and the results show GLP-1 agonists can cut in half heart patients risk of being hospitalized or dying early. What this means is that soon, certain weight loss drugs could be given to patients with heart conditions to help them live longer. Can weight‑loss drugs save heart patients? Does this sound too good to be true? Let’s dive in!

A few years ago, drugs like Wegovy and Zepbound were headline news because of their near‑miraculous ability to help people shed pounds. They belong to a class of medications known as GLP‑1 agonists, which mimic a hormone that makes you feel full and slow the movement of food through your stomach. Originally designed to treat type 2 diabetes, they quickly became famous for weight loss.

Now researchers say these same drugs might do something even more dramatic: cut in half the risk of heart failure patients being hospitalized or dying early. At the European Society of Cardiology conference in Madrid, a team from Mass General Brigham presented a huge study of more than 90,000 people with heart failure with preserved ejection fraction (HFpEF) who were obese and had type 2 diabetes. When they compared people starting the weight‑loss drugs semaglutide or tirzepatide with those starting another diabetes drug, sitagliptin, they found that semaglutide users had a 42 % lower risk of hospitalization or death and tirzepatide users had a 58 % lower risk.  The findings were published in JAMA and were described by experts as “dramatic.”

What Are GLP‑1 Drugs and How Do They Work?

GLP‑1 agonists are synthetic versions of a hormone called glucagon‑like peptide‑1, which helps regulate blood sugar and appetite. When you take one of these drugs, you tend to feel full sooner and stay full longer. Over time that leads to steady, meaningful weight loss, about 12 % of body weight on semaglutide and around 18 % on tirzepatide in clinical trials. These medications also improve blood sugar control, which is why they were first approved for diabetes.

The idea that they could help heart patients isn’t totally new. In May 2025, another study showed that people taking semaglutide had a 20 % lower risk of heart attack, stroke or cardiovascular death, regardless of their starting weight. Scientists think the drugs’ benefits may extend beyond weight loss to anti‑inflammatory effects and improved blood vessel function.

The Promise: Fewer Hospital Visits and Better Survival

The new Mass General Brigham study is impressive because of its size and because it looked at “real world” patients outside of tightly controlled trials. All participants had heart failure with preserved ejection fraction (HFpEF), a common type of heart failure where the heart’s pumping function looks normal, but the muscle is stiff and can’t relax properly. HFpEF accounts for roughly half of all heart failure cases and is rising due to aging, high blood pressure, obesity and type 2 diabetes. Treatments are limited, so any therapy that improves outcomes is a big deal.

By comparing patients who started semaglutide or tirzepatide with those who started sitagliptin, the researchers estimated how likely the GLP‑1 drugs were to prevent hospitalization or death. The results were striking: semaglutide users had a 42 % lower risk and tirzepatide users had a 58 % lower risk.  Interestingly, there was no meaningful difference between the two drugs.  Because this study used health‑care records rather than randomly assigning treatments, it can’t prove cause and effect. People who received GLP‑1 drugs may have been healthier in other ways. Randomised controlled trials will be needed to confirm the benefits and see how long they last.

Understanding HFpEF: The Heart Problem That’s Hard to Treat

To appreciate why this research matters, it helps to know what HFpEF is. In this form of heart failure, the left side of the heart pumps normally but can’t relax properly, causing blood to back up into the lungs and body. Symptoms include shortness of breath, swelling and fatigue. Because the pumping function looks fine on an echocardiogram, HFpEF is sometimes called “heart failure with a normal ejection fraction.” It currently has fewer proven treatments than the better‑known heart failure with reduced ejection fraction (HFrEF).

HFpEF mostly affects older adults, especially those with high blood pressure, obesity or diabetes. With more than 60 million people worldwide living with heart failure, and about half of them having HFpEF, new therapies could make a huge difference.

Things to Cheer and Worry About

As exciting as these findings are, it’s important to look at the whole picture. GLP‑1 drugs come with side effects. A University of California San Francisco article notes that nausea, vomiting, fatigue, diarrhea and constipation are common. Doctors often start patients on low doses and increase gradually to help them adjust. For some people the drugs feel unbearable: one cardiologist described a patient who became severely dehydrated and developed an irregular heart rhythm after starting semaglutide.

In rare cases, the drugs slow the stomach so much that contents remain for days, leading to stomach paralysis or bowel obstruction.  There are also concerns about their use in pregnancy and a lack of long‑term safety data. Meanwhile, a survey of people taking GLP‑1s found that about half experienced nausea, a third had diarrhea and one‑fifth reported vomiting; most said these were mild, but some reported them as serious.

Cost and access are big barriers. Without insurance, a 28‑day supply of brand‑name GLP‑1 drugs like Ozempic, Wegovy or Mounjaro can cost about $1,000 a month.  Even with insurance, many plans only cover the drugs for diabetes, not obesity or heart failure, so patients often pay out of pocket.  Some companies now offer discount programs, Zepbound for $349 – $699 a month and Wegovy for $499, but that’s still a lot of money. When shortages hit in 2024 and 2025, compounding pharmacies stepped in with cheaper versions for about $199 a month, but those products aren’t FDA‑regulated and may vary in quality.

Supply shortages and disparities persist. The U.S. Food and Drug Administration declared the national shortage over in February 2025, but some experts worry that as more people seek the drugs for weight loss or heart health, supply could tighten again. Surveys show that nonwhite patients are less likely to be prescribed GLP‑1s despite being at higher risk for diabetes and obesity. Many people who could benefit most live in rural areas or have low incomes and can’t afford or access the injections.

What This Means for the Future

Doctors are not going to start prescribing these drugs for heart failure right away. As one expert put it, “more evidence would be required before doctors could recommend rolling out weight‑loss drugs to heart patients specifically to cut their risk”. In other words, while the early results look promising, clinicians want to see data from randomized trials before they change practice. Ongoing studies will help determine whether GLP‑1 drugs truly reduce hospitalizations and deaths and which patients benefit most.

In the meantime, these findings highlight the broader value of treating obesity and type 2 diabetes aggressively. Weight loss and good blood sugar control are already known to lower the risk of heart attack, stroke and death. GLP‑1 drugs may become part of the toolkit for managing heart failure, but they won’t replace the basics: a healthy diet, regular exercise, controlling blood pressure and taking medications like SGLT2 inhibitors or beta‑blockers when appropriate.

Final Thoughts

It’s tempting to see GLP‑1 injections as a magic bullet: they help people lose weight and might keep heart patients out of hospital. For some, they will be game‑changing. But every medicine has trade‑offs. These drugs can cause nausea or other side effects; they’re expensive and not always covered by insurance; and the most eye‑popping results so far come from an observational study that needs to be confirmed. If you have heart failure or are considering GLP‑1 therapy, talk to your doctor. Ask about the benefits and risks, and whether there are other treatments you should try first. As research continues, we’ll learn more about who stands to gain the most from these powerful medications and how to make them accessible to everyone who needs them.

Sources

• Press reports summarizing the Mass General Brigham study presented at the European Society of Cardiology conference: semaglutide reduced hospitalization or death by 42 %, and tirzepatide by 58 %.
• Expert commentary on the study, noting both its promise and the need for more evidence.
• The American Heart Association describes HFpEF as a type of heart failure where the heart pumps normally but cannot relax properly; it accounts for about half of all heart failure cases and is linked to aging, hypertension, obesity and diabetes.
• A University of California San Francisco article lists common side effects of GLP‑1 drugs (nausea, vomiting, fatigue, diarrhea, constipation) and notes rare complications like stomach paralysis.
• A RAND survey of U.S. adults taking GLP‑1 agonists reports that about half experienced nausea, a third had diarrhea and one‑fifth had vomiting; most said side effects were mild.
• A WebMD report on cost and access explains that many people struggle to afford GLP‑1 drugs; without insurance they cost about $1,000 a month, and even with insurance coverage is often limited. Discount programs reduce the price but may still be out of reach; compounded versions were available during shortages but carry risks.
• A press report on earlier research notes that semaglutide reduced the risk of heart attack, stroke or cardiovascular death by 20 %.